Staphylococcal pneumonia

Summary

Staphylococcal pneumonia (MONDO:0005970) is a disease. A subtype of bacterial pneumonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	staphylococcal pneumonia
Mondo ID	MONDO:0005970
EFO	EFO:0007496
MeSH	D011023
SNOMED CT	22754005
UMLS	C0032308
MedGen	18532
Is cancer (heuristic)	no

Also known as: Staphylococcus caused pneumonia · Staphylococcus pneumonia

Disease family

This is a subtype of bacterial pneumonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial pneumonia › staphylococcal pneumonia

Related subtypes (7): anaerobic pneumonia, Legionnaires’ disease, Mycoplasma pneumoniae pneumonia, streptococcal pneumonia, Klebsiella pneumonia, pneumonia caused by pseudomonas aeruginosa infection, pneumonia caused by gram negative bacteria

Subtypes (1): staphylococcus aureus pneumonia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Suvratoxumab, Vancomycin.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.